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Abstract
Malignant atrophic papulosis, commonly known as Degos disease, is a rare vasculopathy encompassing both
benign, cutaneous and lethal systemic variants. We report a case of chronic cutaneous lupus erythematosus in a
41-year-old male presenting with prominent Degos-like skin lesions. Multiple atrophic, porcelain-white, scar-like
papules and plaques with dusky, erythematous borders, suggestive of malignant atrophic papulosis, were noted on
the patient’s back. Additional cutaneous findings included photo-distributed facial erythema and discoid lupus-like
plaques on the face, shoulders, and arms. Clinicopathological correlation supported a diagnosis of chronic
cutaneous lupus erythematosus; hydroxychloroquine was initiated with good clinical response. No new or active
lesions were observed at the sixteen-month follow-up. This case highlights a rare skin finding associated with
chronic cutaneous lupus erythematosus and underscores the importance of ruling out primary autoimmune
disease, particularly lupus, before a diagnosis of malignant atrophic papulosis can be made.
Introduction
Malignant atrophic papulosis (MAP), commonly known as Degos disease, is a rare, occlusive microangiopathic
vasculopathy characterized by the presence of “pathognomonic” skin lesions, commonly described as scarred
papules with atrophic, porcelain-white centers and a rim of peripheral erythema and telangiectasia [1]. Classically-
defined MAP is multisystemic and almost universally fatal [1]. Whereas a variety of organ systems can become
involved, gastrointestinal and neurologic sequelae are most common. Death most often results from bowel
perforation [1]. A strictly cutaneous variant of MAP has also been recognized and portends a more favorable
prognosis [1].
Degos-like skin lesions have, on occasion, been reported in association with autoimmune disorders such as lupus
erythematosus, progressive systemic sclerosis, Wegener granulomatosus, and dermatomyositis [2, 3, 4, 5]. We
report a rare case of chronic cutaneous lupus erythematosus (CCLE) associated with prominent Degos-like skin
lesions, highlighting the possibility that these uncommon skin lesions may be an atypical presenting sign of
autoimmune skin diseases such as CCLE.
Case report
A 41-year-old male with no notable past medical history presented with widespread papular skin lesions of three
years duration on his back. Cutaneous exam revealed prominent atrophic, porcelain-white, scar-like papules and
plaques with dusky, erythematous borders and areas of confluence on the back (Figure 1). Additional cutaneous
findings included photo-distributed facial erythema and scattered erythematous, scaly papules and plaques over
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Figure 1
Figure 1. (Gross, pre-treatment)
Atrophic, porcelain-white, scar-like
papules and plaques with dusky,
erythematous borders on patient’s back.
Figure 4
Figure 4. (Gross, One year
post-treatment) Decreased peripheral
erythema with contraction of scar-like
areas and no new active lesions.
Baseline laboratory investigation was notable for a positive anti-nuclear
antibody titer of 1:400 with a speckled, homogenous pattern. Additional
autoimmune markers were negative, including autoantibodies against double-
stranded DNA, extractable nuclear antigens, cardiolipin, and phospholipids.
Figure 2 Figure 3
Figure 2. Photomicrograph of skin biopsy specimen showing a central area of compact
hyperkeratosis and atrophy with an underlying wedge-shaped area of degeneration and
infarcted collagen extending into the mid-dermis. (H&E, x20)
Figure 3. Photomicrograph of skin biopsy specimen showing basal vacuolar
degeneration. (H&E, x40)
Histopathological examination of a lesion from the patient’s back showed a central area of compact hyperkeratosis
and atrophy with an underlying wedge-shaped area of degeneration and infarcted collagen extending into the
mid-dermis (Figure 2), consistent with MAP. Additional histological findings included vacuolar basal degeneration
(Figure 3), a dermal perivascular and perifollicular lymphocytic infiltrate, and increased mucin deposition identified
with alcian blue staining. Direct immunofluorescence studies were negative.
A presumptive diagnosis of CCLE was made after careful clinicopathological
correlation. The patient was started on hydroxychloroquine (5 mg/kg/day) and
low-dose aspirin. Smoking cessation was also advised. On follow-up, there
was decreased peripheral erythema and contraction of the scar-like areas in
the lesions on the patient’s back (Figure 4). The erythematous papules and
plaques improved without scarring. At a sixteen-month follow-up, the patient
remained systemically well with no new or active cutaneous lesions having
developed since the initiation of therapy.
Discussion
Whereas the cutaneous findings in lupus are myriad, this report illustrates an exceedingly rare case of Degos-like
lesions as the first presenting sign of CCLE. The importance of distinguishing between cutaneous lupus and MAP
cannot be overemphasized because MAP is associated with systemic involvement and poor response to
treatment. Death most commonly occurs within two to three years of diagnosis [1].
This patient’s diagnosis of CCLE was based on careful clinicopathological correlation. Whereas his back lesions
were the presenting complaint, a complete cutaneous examination revealed the additional findings of
photodistributed erythema and discoid lupus-like plaques on the face, shoulders, arms, and thighs. Other evidence
supporting the diagnosis was the patient’s positive ANA titer and pattern and his prompt, favorable response to
hydroxychloroquine, a mainstay of CCLE therapy. Because unresponsiveness to therapy has been described as
one of the defining characteristics of MAP, the fact that the patient’s Degos-like lesions and lupus-like plaques
simultaneously improved upon initiation of hydroxychloroquine is also supportive of the diagnosis of CCLE [6].
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Malignant atrophic papulosis is an occlusive, small-vessel vasculopathy that results in tissue infarction [1].
Accordingly, histological examination in patients with MAP commonly reveals wedge-shaped areas of
degenerated, infarcted collagen, as seen in a biopsy from this patient’s back [1]. Whereas this form of wedge-
shaped necrosis is not typically seen in CCLE, the additional findings of basal vacuolation, an interface
dermatitis, a perivascular lymphocytic infiltration, and increased mucin deposition lent support to its diagnosis.
These latter histological findings are characteristic of lupus, but they can also be observed in MAP, somewhat
limiting the usefulness of histopathology in distinguishing between these clinical entities [7]. Nonetheless,
histopathology is important in ruling out other possibilities, such as atrophie blanche, which has also been
described in the setting of lupus and can clinically resemble the lesions characteristic of MAP [8].
It is interesting to note that this patient’s Degos-like lesions showed areas of confluence. This is an unusual
finding that is not described in classical MAP, in which the representative lesions are typically discrete,
well-demarcated, atrophic papules. We believe that this distinct clinical feature of lesional confluence may be
useful in differentiating between classical MAP and other causes of Degos-like lesions. Indeed, a similar
example of coalescing Degos-like lesions has been observed in a patient with underlying dermatomyositis [7].
Given the likelihood of an underlying occlusive microangiopathic process, the patient was treated with a
combination of hydroxychloroquine and low-dose aspirin. Anti-platelet therapy has been reported to be useful
in the benign cutaneous variant of MAP, although clinical response is highly variable [9, 10]. In addition to its
immunomodulatory effects, hydroxychloroquine has been found to have important antithrombogenic properties,
making it a potentially ideal therapeutic agent for such cases of CCLE. Hydroxychloroquine has been
postulated to derive its antithrombotic effects through multiple mechanisms, including the inhibition of platelet
aggregation and adhesion and the lowering of cholesterol levels [11]. It has also been shown to interfere with
antiphospholipid (aPL) antibody production, suggesting that the drug may be especially appropriate in cases of
aPL positive lupus [12]. A recent retrospective study analyzing risk factors for thrombosis in a large, multi-
ethnic systemic lupus erythematosus cohort was the first clinical study to confirm hydroxychloroquine’s
protective anti-thrombotic effects [13]. Our patient was also advised to stop smoking, given the positive
association between smoking and thrombosis and evidence that smoking limits the effectiveness of antimalarial
therapy in patients with CCLE [14].
It is interesting to note that whereas the association between Degos-like lesions and lupus has previously been
described, these reports typically describe patients with systemic lupus erythematosus (SLE) rather than
CCLE. Whereas some of these patients with SLE are likely to have had discoid lesions, to our knowledge, this
is the first report of Degos-like lesions as the presenting complaint in a patient with characteristic discoid
lesions who did not meet the criteria for a diagnosis of SLE. Although it is possible that this patient will, in the
future, develop additional clinical or laboratory findings that would qualify for him a diagnosis of SLE, the
ultimate classification of this patient within the family of lupus diseases is of secondary importance. What is
more significant about this case is the fact that it underscores the importance of excluding treatable conditions
associated with Degos-like lesions given the marked differences in therapy and prognosis for patients. This
case demonstrates that primary autoimmune disease, and in particular, lupus, must be excluded before a
diagnosis of MAP can be made.
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